Nektar Therapeutics (NASDAQ: NKTR) is -3.81% lower on its value in year-to-date trading and has touched a low of $0.50 and a high of $1.93 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NKTR stock was last observed hovering at around $0.92 in the last trading session, with the day’s loss setting it -0.03%.
Currently trading at $0.89, the stock is -7.97% and -13.61% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.27 million and changing -2.55% at the moment leaves the stock -29.39% off its SMA200. NKTR registered 75.38% gain for a year compared to 6-month loss of -39.55%. The firm has a 50-day simple moving average (SMA 50) of $1.045 and a 200-day simple moving average (SMA200) of $1.2692.
The stock witnessed a -4.93% gain in the last 1 month and extending the period to 3 months gives it a -35.64%, and is -1.18% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.13% over the week and 8.24% over the month.
Nektar Therapeutics (NKTR) has around 137 employees, a market worth around $165.02M and $93.14M in sales. Profit margin for the company is -180.70%. Distance from 52-week low is 78.53% and -53.60% from its 52-week high. The company has generated returns on investments over the last 12 months (-72.09%).
with sales reaching $36.65M over the same period.The EPS is expected to grow by 50.60% this year, but quarterly earnings will post 17.53% year-over-year. Quarterly sales are estimated to grow 53.46% in year-over-year returns.
174.0 institutions hold shares in Nektar Therapeutics (NKTR), with institutional investors hold 77.65% of the company’s shares. The shares outstanding are 184.46M, and float is at 177.74M with Short Float at 2.45%. Institutions hold 76.64% of the Float.
The top institutional shareholder in the company is DEEP TRACK CAPITAL, LP with over 17.88 million shares valued at $22.17 million. The investor’s holdings represent 9.1789 of the NKTR Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 15.16 million shares valued at $18.79 million to account for 7.7823 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 12.97 million shares representing 6.6587 and valued at over $16.08 million, while SAMLYN CAPITAL, LLC holds 4.8565 of the shares totaling 9.46 million with a market value of $11.73 million.
Nektar Therapeutics (NKTR) Insider Activity
The most recent transaction is an insider sale by Wilson Mark Andrew, the company’s Chief Legal Officer. SEC filings show that Wilson Mark Andrew sold 33,402 shares of the company’s common stock on Dec 23 ’24 at a price of $0.90 per share for a total of $30062.0. Following the sale, the insider now owns 0.35 million shares.
Nektar Therapeutics disclosed in a document filed with the SEC on Dec 24 ’24 that Wilson Mark Andrew (Chief Legal Officer) sold a total of 16,560 shares of the company’s common stock. The trade occurred on Dec 24 ’24 and was made at $0.89 per share for $14738.0. Following the transaction, the insider now directly holds 0.34 million shares of the NKTR stock.
Still, SEC filings show that on Dec 24 ’24, Wilson Mark Andrew (Officer) Proposed Sale 16,560 shares at an average price of $0.89 for $14801.0. The insider now directly holds shares of Nektar Therapeutics (NKTR).
